AGP Executive Report
Last update: 4 hours agoBiotech: Boston-area companies are advancing clinical programs: Solu Therapeutics, Agios and CRISPR Therapeutics will present new blood-disease data at the December ASH meeting, while Cambridge-based Intellia completed enrollment in a Phase 3 gene-editing trial. Manufacturing: Framingham-based Re:Build reportedly raised $2.1 billion to scale hard-tech manufacturing, a major financing milestone for the state’s industrial sector. Energy and Infrastructure: Massachusetts is set to add a 700-megawatt battery, while a separate study says a pipeline upgrade could reduce winter energy bills by $367 million. Thea Energy also teamed with MIT’s Plasma Science and Fusion Center to test a magnet for its planned fusion system. State Policy: Voters approved a new nature conservation fund and rejected a bid to roll back recreational marijuana sales, keeping the state’s legal cannabis market in place.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
